Relief Therapeutics Discovers A Promising COVID-19 Killer

Summary

• Relief Therapeutics is in advanced clinical trials with their drug RLF-100 which aims to halt COVID-19 and reverse its devastating effects.
• Just-released Compassionate Use results showed stunning results: ventilator-dependent COVID-19 patients with deadly comorbidities coming off the ventilator and returning home in only five days after treatment with RLF-100.
• Relief Therapeutic's RLF-100 is both easy to manufacture at scale and inexpensive, meaning that success in clinical trials could translate to rapid worldwide production and availability.
• If in-progress clinical trials reflect the Compassionate Use results, RLF-100 will likely garner immediate approval, and shares could go much higher.

Relief Therapeutics Holdings AG (OTCQB:RLFTF) is a Swiss Company that trades on the U.S. OTC Exchange in addition to its Swiss Stock Exchange Listing (RLF). Only a week ago, Relief Therapeutics was trading under .10 per share. It was the rediscovery of the properties of their drug RLF-100, a proprietary synthetic form of Vasoactive Intestinal Polypeptide (VIP) also known as aviptadil, which has led to the justifiable interest in the company.

In a previous article, I described my rationale for following potential Covid-19 therapeutics over potential vaccines, and the progression of the disease from viral to immunologic that has served to categorize the various approaches to fighting Covid-19 and its effects. I won't repeat that discussion here, as I'm eager to get to the point that Relief Therapeutics' drug is the most promising that I have encountered to tackle Covid-19 in four months of research.

Let's start with the latest results, then get to the science, followed by Relief Therapeutics' corporate structure, management, and balance sheet.

The Results So Far

On August 2, 2020, Relief Therapeutics announced a report from doctors at Houston Methodist Hospital that RLF-100 "showed rapid recovery from respiratory failure in the most critically ill patients with COVID-19."

At the same time, unaffiliated independent researchers working in Brazil reported that VIP inhibits the replication of SARS-CoV-2 virus in human lung cells and immune cells.

The release from Relief and NeuroRx further stated:

The report describes a 54-year-old man who developed COVID-19 while being treated for rejection of a double lung transplant and who came off a ventilator within four days. Similar results were subsequently seen in more than 15 patients [emphasis mine] treated under emergency use IND and an FDA expanded access protocol, which is open to patients too ill to be admitted to the ongoing Phase 2/3

Analyst’s Disclosure:I am/we are long RLFTF. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.

Additional disclosure: I am not registered as an investment advisor in the United States or in any other jurisdiction. Information in this article is presented “as is,” without warranty of any kind – whether express or implied. I make no representation, express or implied, as to the accuracy, timeliness, or completeness of any such information or with regard to the results to be obtained from its use. All expressions of opinion are subject to change without notice, and I do not undertake to update or supplement this report or any of the information contained herein. This is not an offer to sell or a solicitation of an offer to buy any security, nor shall any security be offered or sold to any person, in any jurisdiction in which such offer would be unlawful under the securities laws of such jurisdiction. I have not received any form of compensation from the companies that I have written about in this article, nor have I received any form of compensation from company affiliates or other company shareholders.